This is the risk that gets least attention and matters most to how hormone therapy is actually prescribed — because unlike most risk discussions, there is a clear, actionable answer here. The evidence consistently shows that how estrogen enters your body changes the clot picture substantially. Here is what that means in practice.

Where we stand: Menova is an independent publication. We sell no hormones, we are not your doctor, and this is general education, not medical advice or a recommendation.

The core finding

Oral estrogen is associated with an increased risk of venous thromboembolism — deep vein thrombosis and pulmonary embolism. Transdermal estrogen, at standard doses, has not been shown to carry the same increase.

That distinction is consistent enough across observational studies that it now shapes prescribing guidance, and it is why a clinician may steer you toward a patch, gel, or spray rather than a tablet.

Why the route matters

Swallowed estrogen is absorbed through the gut and passes through the liver before reaching the rest of your body — the "first-pass" effect. The liver responds by altering production of clotting factors, which is what shifts the balance toward clotting.

Transdermal estrogen is absorbed through the skin directly into the bloodstream, bypassing that first pass. The liver never sees the concentrated dose, so the clotting factors are not altered in the same way.

The same mechanism explains other differences: transdermal estrogen also has less effect on triglycerides and on blood pressure in some women.

Putting the numbers in proportion

Venous thromboembolism is uncommon in healthy women in their fifties, so an increase applies to a small baseline. Menopause societies generally describe the absolute increase with oral therapy as small — in the range of roughly one to two additional cases per 1,000 women per year of use in this age group, with the risk highest in the first year of use and higher in women who already have risk factors.

Two things that should be said alongside that:

  • Your personal baseline matters more than the average. Obesity, immobility, previous clot, thrombophilia, and smoking all shift it substantially.
  • Pregnancy and combined oral contraception carry higher clot risk than menopausal hormone therapy, which is worth knowing for proportion — the doses involved are considerably lower in HRT.

Who should particularly consider transdermal

Guidance points toward the transdermal route where clot risk is elevated:

  • Previous venous thromboembolism, or a known thrombophilia such as factor V Leiden
  • A first-degree relative with a clot, particularly at a young age
  • BMI over 30
  • Migraine with aura, where transdermal is generally preferred; see menopause and migraines
  • Smokers, and women with cardiovascular risk factors
  • Reduced mobility, or a planned major surgery

A history of clot is not automatically an absolute barrier to hormone therapy — it is a reason for specialist input and, usually, the transdermal route. It is worth knowing that, because many women in this position are told no without a conversation.

What about progesterone?

Some evidence suggests micronized progesterone may have a more neutral effect on clotting risk than certain synthetic progestins, particularly older ones. This is observational rather than trial evidence and should not be overstated, but it is a reasonable thing to ask about — see progesterone in menopause.

Local vaginal estrogen is a different situation entirely. It acts locally with minimal systemic absorption and is not associated with the systemic risks discussed here; see is vaginal estrogen safe.

Signs of a clot — know these

This is the practical part of the article. Contact a doctor urgently for:

DVT (usually in a leg):

  • Pain, tenderness, or cramping, often in the calf
  • Swelling of one leg
  • Warmth, redness, or discoloration
  • A leg that looks visibly different from the other

Pulmonary embolism — call emergency services:

  • Sudden breathlessness
  • Chest pain, often sharp and worse on breathing in
  • Coughing up blood
  • A rapid heart rate, dizziness, or collapse

These are not symptoms to research further before acting. Being wrong costs an appointment; being right and waiting can cost far more.

Situations that raise risk temporarily

Worth planning for rather than discovering:

  • Surgery. Tell your surgical team you take hormone therapy. They will advise whether to pause it and what thromboprophylaxis you need.
  • Long-haul flights and long journeys. Move regularly, stay hydrated; ask about compression stockings if you have other risk factors.
  • Prolonged immobility — a fracture, illness, or bed rest.
  • Acute illness with dehydration.

How to have this conversation

Bring the specifics that change the answer:

"There's a history of clots in my family — my mother had a DVT at 45. Given that, would transdermal estrogen be more appropriate for me than a tablet, and is there anything you'd want to check first?"

Naming the route makes it a practical decision rather than a yes-or-no on hormone therapy as a whole. Our guides to HRT types and forms and HRT risks and benefits cover the wider picture, and breast cancer risk in real numbers covers the other risk women are usually most focused on.

The free printable visit prep sheet has a history section that includes clots and thrombophilia specifically, so the relevant facts are in the room without you having to remember them under pressure. The free 2-minute self-check organizes the symptom side — no account, not a diagnosis, and your answers never leave your device.

The honest summary

For most healthy women, transdermal estrogen has not been shown to increase clot risk meaningfully, and oral estrogen carries a small absolute increase concentrated in the first year and in women with existing risk factors. That is a genuinely actionable piece of information — one of the few places in menopause care where a simple choice materially changes a risk.

For where the clot findings came from and why route now matters, see what the WHI actually found. Also: HRT types and forms, migraine with aura and HRT, HRT before surgery, and when you can't decide.

This article is general education, not medical advice, and not a recommendation for or against any route of hormone therapy. Risk depends on your individual history. Decide with a licensed clinician, and seek urgent care for any symptoms of a clot.

Sources: The Menopause Society, NICE NG23 — Menopause, CDC — Blood Clots, and ACOG.